Cargando…

The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors

Uric acid is the end product of purine metabolism in humans. Hyperuricemia is a metabolic disease caused by the increased formation or reduced excretion of serum uric acid (SUA). Alterations in SUA homeostasis have been linked to a number of diseases, and hyperuricemia is the major etiologic factor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ning, Xu, Hu, Sun, Qianqian, Yu, Xiaojuan, Chen, Wentong, Wei, Hongquan, Jiang, Jie, Xu, Youzhi, Lu, Wenjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019370/ https://www.ncbi.nlm.nih.gov/pubmed/33854690 http://dx.doi.org/10.1155/2021/1470380

Ejemplares similares

Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
por: Chen, Changyi, et al.
Publicado: (2016)

Plasma Xanthine Oxidoreductase (XOR) Activity in Cardiovascular Disease Outpatients
por: Matsushita, Masato, et al.
Publicado: (2020)

Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout
por: Nishino, Takeshi, et al.
Publicado: (2014)

Evaluation of Neuronal Protective Effects of Xanthine Oxidoreductase Inhibitors on Severe Whole-brain Ischemia in Mouse Model and Analysis of Xanthine Oxidoreductase Activity in the Mouse Brain
por: SUZUKI, Go, et al.
Publicado: (2015)

Pro-Aging Effects of Xanthine Oxidoreductase Products
por: Battelli, Maria Giulia, et al.
Publicado: (2020)

Xanthine oxidoreductase activity is correlated with hepatic steatosis
por: Yagi, Chisako, et al.
Publicado: (2022)

Discriminating Susceptibility of Xanthine Oxidoreductase Family to Metals
por: Steunou, Anne-Soisig, et al.
Publicado: (2023)

Relationship between Xanthine Oxidoreductase Redox and Oxidative Stress among Chronic Kidney Disease Patients
por: Terawaki, Hiroyuki, et al.
Publicado: (2018)

Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice
por: Nakamura, Takashi, et al.
Publicado: (2021)

Pharmacodynamic evaluation of the XOR inhibitor WN1703 in a model of chronic hyperuricemia in rats induced by yeast extract combined with potassium oxonate
por: Li, Yuanyuan, et al.
Publicado: (2022)

Orange Juice and Hesperetin Supplementation to Hyperuricemic Rats Alter Oxidative Stress Markers and Xanthine Oxidoreductase Activity
por: Haidari, Fatemeh, et al.
Publicado: (2009)

Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase
por: Battelli, Maria Giulia, et al.
Publicado: (2018)

Xanthine oxidoreductase: One enzyme for multiple physiological tasks
por: Bortolotti, Massimo, et al.
Publicado: (2021)

Hepatocyte-Specific Ablation or Whole-Body Inhibition of Xanthine Oxidoreductase in Mice Corrects Obesity-Induced Systemic Hyperuricemia Without Improving Metabolic Abnormalities
por: Harmon, Daniel B., et al.
Publicado: (2019)

Chemical Nature and Reaction Mechanisms of the Molybdenum Cofactor of Xanthine Oxidoreductase
por: Okamoto, Ken, et al.
Publicado: (2013)

Xanthine oxidoreductase in cancer: more than a differentiation marker
por: Battelli, Maria Giulia, et al.
Publicado: (2015)

Xanthine Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects
por: Battelli, Maria Giulia, et al.
Publicado: (2016)

Xanthine oxidoreductase: A leading actor in cardiovascular disease drama
por: Polito, Letizia, et al.
Publicado: (2021)

Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductase
por: Sekine, Mai, et al.
Publicado: (2023)

Therapeutic effects and mechanisms of N-(9,10-anthraquinone-2-ylcarbonyl) xanthine oxidase inhibitors on hyperuricemia
por: Gao, Tianshu, et al.
Publicado: (2022)

The Effects of Xanthine Oxidoreductase Inhibitors on Oxidative Stress Markers following Global Brain Ischemia Reperfusion Injury in C57BL/6 Mice
por: Yamaguchi, Masahiro, et al.
Publicado: (2015)

Comprehensive analysis of the relationship between xanthine oxidoreductase activity and chronic kidney disease
por: Zhang, Yiyuan, et al.
Publicado: (2023)

Evaluation of the Effectiveness of Xanthine Oxidoreductase Inhibitors on Haemodialysis Patients using a Marginal Structural Model
por: Ishii, Takeo, et al.
Publicado: (2017)

Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia
por: Romo-González, Marta, et al.
Publicado: (2020)

On the Sparsity of XORs in Approximate Model Counting
por: Agrawal, Durgesh, et al.
Publicado: (2020)

Mechanism of Porcine Liver Xanthine Oxidoreductase Mediated N-Oxide Reduction of Cyadox as Revealed by Docking and Mutagenesis Studies
por: Chen, Chigang, et al.
Publicado: (2013)

Diurnal Variations in Serum Uric Acid, Xanthine, and Xanthine Oxidoreductase Activity in Male Patients with Coronary Artery Disease
por: Shimizu, Megumi, et al.
Publicado: (2023)

Mutations Associated with Functional Disorder of Xanthine Oxidoreductase and Hereditary Xanthinuria in Humans
por: Ichida, Kimiyoshi, et al.
Publicado: (2012)

Independent links between plasma xanthine oxidoreductase activity and levels of adipokines
por: Furuhashi, Masato, et al.
Publicado: (2019)

Hydrogen sulfide stimulates xanthine oxidoreductase conversion to nitrite reductase and formation of NO
por: Pardue, Sibile, et al.
Publicado: (2020)

Xanthine Oxidoreductase Is Involved in Chondrocyte Mineralization and Expressed in Osteoarthritic Damaged Cartilage
por: Nasi, Sonia, et al.
Publicado: (2021)

Association of Mutations Identified in Xanthinuria with the Function and Inhibition Mechanism of Xanthine Oxidoreductase
por: Sekine, Mai, et al.
Publicado: (2021)

Xanthine oxidoreductase is required for genotoxic stress-induced NKG2D ligand expression and gemcitabine-mediated antitumor activity
por: Xu, Xiulong, et al.
Publicado: (2016)

Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats
por: Shirakura, Takashi, et al.
Publicado: (2016)

Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis
por: Kurajoh, Masafumi, et al.
Publicado: (2022)

Xanthine oxidoreductase activity in platelet-poor and rich plasma as a oxidative stress indicator in patients required renal replacement therapy
por: Cecerska-Heryć, Elżbieta, et al.
Publicado: (2022)

Xanthine Oxidoreductase Reference Values in Platelet-Poor Plasma and Platelets in Healthy Volunteers
por: Cecerska-Heryć, Elżbieta, et al.
Publicado: (2015)

Putting xanthine oxidoreductase and aldehyde oxidase on the NO metabolism map: Nitrite reduction by molybdoenzymes()
por: Maia, Luisa B., et al.
Publicado: (2018)

Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a  Detoxifying Enzyme
por: Battelli, Maria Giulia, et al.
Publicado: (2016)

Gender Differences in the Impact of Plasma Xanthine Oxidoreductase Activity on Coronary Artery Spasm
por: Watanabe, Ken, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k91fi2bjble88gupve2nj96rnb